Skip to content

Nuvation Bio NUVB Return on equity

Return on equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
38.8%+7.3pp
Pfizer logo
PfizerPFE
10.6%
Nuvalent, Inc. logo
Nuvalent, Inc.NUVL
-41.2%+7.5pp
Immunome logo
ImmunomeIMNM
-50.1%-10.8pp
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-55.2%+8.0pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-70%+8.4pp

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Calculated from Nuvation Bio’s reported figures.

Based on trailing twelve months.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's return on equity?
Nuvation Bio (NUVB) reported return on equity of -39.5% in Q1 2026.
How has Nuvation Bio's return on equity changed year-over-year?
Nuvation Bio's return on equity increased by 67.0% year-over-year, from -119.7% to -39.5%.
What is the long-term trend for Nuvation Bio's return on equity?
Over 5 years (2020 to 2025), Nuvation Bio's return on equity has grown at a 13.7% compound annual growth rate (CAGR), from -28% to -53.2%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.